Literature DB >> 11032391

The high affinity neurotensin receptor gene (NTSR1): comparative sequencing and association studies in schizophrenia.

J Austin1, P Buckland, A G Cardno, N Williams, G Spurlock, B Hoogendoorn, S Zammit, G Jones, R Sanders, L Jones, G McCarthy, S Jones, N J Bray, P McGuffin, M J Owen, M C O'Donovan.   

Abstract

Neurotensin and its high affinity receptor (NTSR1) localise within dopaminergic neurones in the mesocortical, mesolimbic and nigrostriatal systems and it is now clear that neurotensin can selectively modulate dopaminergic neurotransmission. This has led to the hypothesis that altered neurotensin function contributes to the pathogenesis of schizophrenia and other psychoses. This hypothesis has been supported circumstantially by a number of lines of evidence. (1) Central administration of neurotensin produces effects similar to those produced by the peripheral administration of atypical antipsychotics. (2) Observations of low levels of neurotensin in the CSF of schizophrenics. (3) Reduced numbers of neurotensin receptors in the brains of schizophrenics. Given the above link between neurotensin and dopamine, and the evidence implicating altered neurotensin function in psychosis, we have postulated that DNA sequence variation in neurotensin or its receptors might be associated with schizophrenia. In keeping with this hypothesis, an association has recently been reported between schizophrenia and the gene encoding the neurotensin high affinity receptor (NTSR1). However, caution is required because the associated marker, a tetranucleotide repeat, is located 3 kb away from the 3' end of the gene and there is no evidence that it is functional. Therefore, as a follow-up to our earlier work on neurotensin, we have now sought to test the hypothesis that DNA sequence variants that alter the structure or expression of the NTSR1 gene (VAPSEs) are associated with schizophrenia. However, while we found 14 novel sequence variants in 28 probands with psychosis, none resulted in an amino acid change, and neither direct nor indirect association studies suggested these are involved in susceptibility to schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032391     DOI: 10.1038/sj.mp.4000761

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  6 in total

Review 1.  Recent advances in the genetics of schizophrenia.

Authors:  D M Waterwort; A S Bassett; L M Brzustowicz
Journal:  Cell Mol Life Sci       Date:  2002-02       Impact factor: 9.261

2.  Association between neurotensin receptor 1 (NTR1) gene polymorphisms and schizophrenia in a Han Chinese population.

Authors:  Hui Ma; Yinglin Huang; Bo Zhang; Jingying Li; Yuan Wang; Xiaofeng Zhao; Qiu Jin; Gang Zhu
Journal:  J Mol Neurosci       Date:  2013-03-13       Impact factor: 3.444

3.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

4.  Neurotensin receptor 1 gene (NTSR1) polymorphism is associated with working memory.

Authors:  Jin Li; Chuansheng Chen; Chunhui Chen; Qinghua He; He Li; Jun Li; Robert K Moyzis; Gui Xue; Qi Dong
Journal:  PLoS One       Date:  2011-03-04       Impact factor: 3.240

5.  Contributions of dopamine-related genes and environmental factors to highly sensitive personality: a multi-step neuronal system-level approach.

Authors:  Chunhui Chen; Chuansheng Chen; Robert Moyzis; Hal Stern; Qinghua He; He Li; Jin Li; Bi Zhu; Qi Dong
Journal:  PLoS One       Date:  2011-07-13       Impact factor: 3.240

6.  Cortical patterning of abnormal morphometric similarity in psychosis is associated with brain expression of schizophrenia-related genes.

Authors:  Sarah E Morgan; Jakob Seidlitz; Kirstie J Whitaker; Rafael Romero-Garcia; Nicholas E Clifton; Cristina Scarpazza; Therese van Amelsvoort; Machteld Marcelis; Jim van Os; Gary Donohoe; David Mothersill; Aiden Corvin; Andrew Pocklington; Armin Raznahan; Philip McGuire; Petra E Vértes; Edward T Bullmore
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-19       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.